PROGRAM 3 (IMMUNOLOGY AND CANCER)

免疫学和癌症计划（计划3）一直是UCCRC的组成部分， 20多年该委员会有来自5个部门的19名成员， 同行评审的资金（年度直接费用），来自NCI的2，154，936美元。在过去的赠款期间， 项目成员共发表了387篇同行评审的出版物，其中11%是 其中15%是项目内合作，15%是项目间合作。 已经确定，肿瘤可以表达可以被特异性T细胞识别的抗原， 抗体的临床上已建立的免疫疗法包括同种异体骨髓或血液 干细胞移植，单克隆抗体赫赛汀和Rituxan，以及细胞因子IL-2和 IFN-α。然而，随着免疫系统的基础知识继续快速增长， 速度，改善现有免疫疗法的潜力，以及开发新的 免疫力的方法，继续扩大。免疫学和癌症的总体目标 该计划旨在促进与癌症背景相关的最佳研究，以支持 环境，将新的免疫学概念引入抗肿瘤免疫的临床前模型， 将基础发现转化为临床应用。该方案的一项主要成就是 临床/翻译部分的扩展。这些目标得到了几个关键核心的支持 设施，特别是流式细胞术，惠誉单克隆抗体，免疫组织化学， 人类免疫监测核心。免疫学和癌症计划也取决于 cGMP设施（UCCRC开发核心）的服务，用于制备临床级免疫制剂 用于临床给药的产品。通过纳入详细的科学终点监测 在临床研究中，正在产生新的关键信息，这些信息导致了新的 这些假设可以在基础实验室中进行研究。免疫学和 癌症项目已经发展成为双向转化研究的一个明显例子。

The Immunology and Cancer Program (Program 3) has been an integral component of the UCCRC for more than 20 years. It has 19 members from 5 departments, and is supported by a total of $7,660,269 in peer-reviewed funding (annual direct costs), with $2,154,936 from the NCI. Over the past grant period, program members have produced a total of 387 peer-reviewed publications, including 11% that were intraprogrammatic and 15% that were interprogrammatic collaborations. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Established immunologic therapies in the clinic include allogeneic bone marrow or blood stem cell transplantation, the monoclonal antibodies Herceptin and Rituxan, and the cytokines IL-2 and IFN-cc. However, as fundamental knowledge of the immune system continues to increase at a rapid pace, the potential for improving upon existing immune-based therapies, as well as for developing new immunotherapeutic approaches, continues to expand. The overall goals of the Immunology and Cancer Program are to foster the best possible research that has relevance for the cancer setting, to support an environment that brings new immunology concepts into preclinical models of anti-tumor immunity, and to translate fundamental discoveries into clinical application. A major accomplishment of the Program is the expansion of the clinical/translational component. These goals are supported by severa key Core Facilities, in particular the Flow Cytometry, Fitch Monoclonal Antibody, Immunohistochemistry, and the Human Immunologic Monitoring Cores. The Immunology and Cancer Program also depends on the services of the cGMP Facility (a UCCRC developing core) for preparation of clinical-grade immunotherapeutic products for clinical administration. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is being generated that has led to the development of new hypotheses that can then be interrogated back in the basic laboratory. Thus, the Immunology and Cancer Program has evolved into a clear example of bi-directional translational research.